10 Low Risk High Reward Stocks Set to Triple by 2030

5. OmniAb, Inc. (NASDAQ:OABI)

Number of Hedge Fund Holders: 21

Potential upside: 300%

OmniAb, Inc. (NASDAQ:OABI) is a biotech company that creates tech for antibody discovery targeting next-gen medicines. Its platforms include OmniRat, OmniMouse, OmniChicken, OmniTaur, and OmniDeep. These platforms blend biological intelligence with artificial intelligence to develop human therapeutic antibodies through various pharma, biotech, and academia partnerships.

On the financial side, OmniAb, Inc. (NASDAQ:OABI) ended 2024 with $59.4 million in cash. Additionally, Q4 revenue jumped to $10.8 million, up from $4.8 million the previous year, thanks to new deals and milestone payments. However, the company lost $62 million for the year, more than 2023’s $50.6 million loss. This was partly due to a $3.8 million hit from moving away from small-molecule ion channels. OmniAb expects fewer expenses in 2025, with revenue between $20 million and $25 million.

Furthermore, OmniAb, Inc. (NASDAQ:OABI) also saw an increase in partner count, which grew 18% to 91 by the end of 2024. Whereas active programs rose 12% to 362, with 32 programs either in clinical trials or approved. In addition, recent wins include new platform licenses with Incyte and Photinia, clinical trial starts with J&J and Innolake, and progress with Genmab, Teva, and Immunovant. The company also just announced a big partnership with VERAXA Biotech in March to develop a new bispecific antibody-drug conjugate for solid tumors.

With diverse partners, advancing clinical programs, and efficient cash management, OmniAb, Inc. (NASDAQ:OABI) is one of the best low risk stocks with long-term potential.